The Challenges of Treating FLT3-ITD AML
Mark J. Levis, MD, PhD, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia.
Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).
Clinical Pearls:
- While an AML patient with a low white blood cell count can be maintained with transfusions and antibiotics, the population of patients with a FLT3-ITD mutation are difficult to palliate
- The majority of patients with a high white blood cell count and a FLT3-ITD mutation can be treated into remission but they will eventually relapse
- Physicians attempt to keep these patients in remission long enough to be able to get a transplant
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More
